Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide that acts as a powerful immune regulator, modulating inflammation and autoimmune responses through multiple immune cell types.
28 amino acidsVIP is a small neuropeptide with outsized immune effects — acting on macrophages, dendritic cells, and T cells to modulate inflammation
What the researchers found
VIP (vasoactive intestinal peptide), a 28-amino-acid neuropeptide, functions far beyond its original discovery as a vasodilator. This review establishes VIP as a major immune regulator produced by both neurons and immune cells. VIP acts on macrophages, dendritic cells, and CD4+ T lymphocytes through specific receptors, modulating inflammatory and autoimmune responses.
The review covers VIP's involvement in inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and other autoimmune conditions, as well as its current clinical applications and future therapeutic potential.
Why it matters
VIP represents one of the clearest examples of how neuropeptides bridge the nervous and immune systems. Understanding VIP's immune functions opens therapeutic avenues for autoimmune diseases — conditions where the immune system attacks the body's own tissues. Unlike many immunosuppressants, VIP modulates rather than broadly suppresses immunity, potentially offering more targeted treatments with fewer side effects.
The numbers in context
28 amino acids · Expressed in CNS and peripheral nervous system · Acts on macrophages, dendritic cells, CD4+ T cells · Multiple receptor subtypes (VPAC1, VPAC2)
How the study worked
This is a comprehensive review of published literature on VIP's immune functions, covering VIP production by neurons and immune cells, receptor signaling pathways, effects on specific immune cell types (macrophages, dendritic cells, T lymphocytes), roles in inflammatory and autoimmune disorders, and current and potential therapeutic applications.
Who was studied
Review of human and animal studies on VIP's immune regulatory functions
What this study cannot tell us
As a review, this paper synthesizes existing knowledge rather than presenting new data. Much of the evidence for VIP's therapeutic potential comes from animal models of autoimmune disease. The translation of VIP-based therapies to human clinical use has been limited by the peptide's short half-life and delivery challenges.
How to read the evidence
This is a comprehensive review by established VIP researchers, published in a peer-reviewed journal. It synthesizes strong preclinical evidence across multiple disease models, but clinical human data on VIP-based therapies remains limited.
When this study was published
Published in 2013, this review provides a thorough foundation for understanding VIP's immune functions. While the basic science remains valid, more recent studies have advanced VIP analog development and clinical applications since this publication.
The bigger picture
VIP sits at the intersection of neuroscience and immunology — a field called neuroimmunology that is reshaping how we understand diseases from IBD to MS. As the therapeutic potential of immunomodulatory peptides gains attention (see also thymosin alpha-1, KPV), VIP represents one of the best-characterized examples of a neuropeptide with direct immune applications. The challenge remains delivering it effectively, as VIP is rapidly degraded in the body.
Questions still open
- Can VIP analogs with extended half-lives be developed for practical clinical use in autoimmune diseases?
- How does VIP's immune modulation compare to other anti-inflammatory peptides like KPV or thymosin alpha-1?
- Could VIP-based therapies selectively treat autoimmune inflammation without compromising infection defense?
Common questions
What does VIP do in the body?
Could VIP be used to treat autoimmune diseases?
Read the original research
Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.
Amino acids, 45(1), 25-39
Citation
Delgado, Mario; Ganea, Doina. (2013). Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.. Amino acids, 45(1), 25-39. https://doi.org/10.1007/s00726-011-1184-8